PL4504202T3 - Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077 - Google Patents

Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077

Info

Publication number
PL4504202T3
PL4504202T3 PL23721096.8T PL23721096T PL4504202T3 PL 4504202 T3 PL4504202 T3 PL 4504202T3 PL 23721096 T PL23721096 T PL 23721096T PL 4504202 T3 PL4504202 T3 PL 4504202T3
Authority
PL
Poland
Prior art keywords
gdc
cancer
treatment
combination therapies
therapies
Prior art date
Application number
PL23721096.8T
Other languages
English (en)
Inventor
Mark Andrew MERCHANT
Jennifer Lee SCHUTZMAN
Zhen Shi
Chunyan Song
Neekesh Vijay DHARIA
Stephanie Royer JOO
Original Assignee
Genentech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc. filed Critical Genentech Inc.
Publication of PL4504202T3 publication Critical patent/PL4504202T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL23721096.8T 2022-04-06 2023-04-04 Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077 PL4504202T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263328149P 2022-04-06 2022-04-06
PCT/US2023/017455 WO2023196329A1 (en) 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL4504202T3 true PL4504202T3 (pl) 2026-05-04

Family

ID=86286527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23721096.8T PL4504202T3 (pl) 2022-04-06 2023-04-04 Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077

Country Status (13)

Country Link
US (2) US12383557B2 (pl)
EP (1) EP4504202B1 (pl)
JP (1) JP2025511352A (pl)
KR (1) KR20240167654A (pl)
CN (1) CN119013026A (pl)
AU (1) AU2023249068A1 (pl)
CA (1) CA3255718A1 (pl)
ES (1) ES3067080T3 (pl)
IL (1) IL315250A (pl)
MX (1) MX2024012230A (pl)
PL (1) PL4504202T3 (pl)
TW (1) TW202345846A (pl)
WO (1) WO2023196329A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250000802A1 (en) * 2023-06-09 2025-01-02 Hoffmann-La Roche Inc. Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
TWI829003B (zh) 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
EP4243827A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR102975432B1 (ko) 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
TWI895563B (zh) 2020-12-08 2025-09-01 美商建南德克公司 用於治療實性瘤之包含ｋｒａｓｇ１２ｃ抑制劑及ｅｇｆｒ抑制劑之組成物及方法
AR128449A1 (es) 2022-02-07 2024-05-08 Genentech Inc Proceso para la síntesis de compuestos de quinazolina
CN118742544A (zh) 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式

Also Published As

Publication number Publication date
US12383557B2 (en) 2025-08-12
EP4504202A1 (en) 2025-02-12
US20230321102A1 (en) 2023-10-12
IL315250A (en) 2024-10-01
CN119013026A (zh) 2024-11-22
KR20240167654A (ko) 2024-11-27
AU2023249068A1 (en) 2024-09-05
ES3067080T3 (en) 2026-05-19
TW202345846A (zh) 2023-12-01
CA3255718A1 (en) 2023-10-12
JP2025511352A (ja) 2025-04-15
US20260053802A1 (en) 2026-02-26
MX2024012230A (es) 2024-11-08
EP4504202B1 (en) 2026-02-04
WO2023196329A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
IL325744A (en) Combination therapies for cancer treatment
IL327418A (en) RAS-PI3K inhibitors for the treatment of cancer and immunological diseases
EP4010081A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
ZA202206743B (en) Therapy for the treatment of cancer
IL280337A (en) LAG-3 combination therapy for cancer treatment
IL307465A (en) Combined therapies for cancer treatment
IL308766A (en) Compositions and methods for treating prostate cancer
EP4048406A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS
SG11202103141YA (en) Combination therapy for the treatment of cancer
SI4340842T1 (sl) Sotorasib za uporabo pri zdravljenju raka
EP3813854A4 (en) IN VIVO REGULATED POLYTHERAPY FOR THE TREATMENT OF CANCER
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
IL284162A (en) Integrated healing for cancer treatment
IL315250A (en) Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer
IL315443A (en) Combined gene and radiation therapy for cancer treatment
PL4294395T3 (pl) Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077
IL288178A (en) Combined gmci and ddri treatment for cancer
IL305780A (en) Cancer treatment methods
IL319193A (en) Combination therapies using PRMT5 inhibitors and BCL-2 family inhibitors for cancer treatment
IL320482A (en) Combination therapy for cancer treatment
CA3297676A1 (en) Combination therapies for the treatment of cancer
CA3280418A1 (en) Combination therapies for the treatment of cancer
IL318624A (en) Combination therapies for cancer treatment
CA3294919A1 (en) Omomyc and kras inhibitors combination therapy for the treatment of cancer
HK40097938A (en) Combination therapy for the treatment of cancer